CECLOR
LOE ApproachingNDAORALCAPSULE
Approved
Apr 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CECLOR is an oral cephalosporin antibiotic approved in 1979 for bacterial infections. The exact indications are not specified in available data, but cephalosporins typically treat respiratory, urinary, and skin infections. It represents a mature small-molecule antibiotic class with decades of clinical use.
LOE Approaching
As a legacy product approaching loss of exclusivity, the brand team is likely small and focused on managed decline and cost-efficiency rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CECLOR offers limited career advancement due to its mature, declining commercial status and lack of pipeline activity. This role is best suited for professionals managing legacy products or seeking stability in a well-established therapeutic area rather than growth and innovation.
Regulatory Affairs SpecialistProduct Manager
Worked on CECLOR at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.